A Phase 2 Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Dose-Ranging Study Assessing Efficacy and Safety of SB208 and Vehicle Gel in Subjects With Interdigital Tinea Pedis

Trial Profile

A Phase 2 Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Dose-Ranging Study Assessing Efficacy and Safety of SB208 and Vehicle Gel in Subjects With Interdigital Tinea Pedis

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 12 Apr 2017

At a glance

  • Drugs Nitric oxide (Primary)
  • Indications Onychomycosis; Tinea pedis
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Novan Inc
  • Most Recent Events

    • 12 Apr 2017 Primary endpoint (Fungal culture result) has been met, according to a Novan Inc media release.
    • 12 Apr 2017 Results published in a Novan Inc media release.
    • 20 Mar 2017 According to a Novan media release, company expects to report top-line results in the second quarter of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top